Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies

British Journal of Cancer

Volumn 107, Issue 8, 2012, Pages 1227-1232

  Procopio, G ^a   Verzoni, E ^a   Iacovelli, R ^b   Biasoni, D ^a   Testa, I ^a   Porcu, L ^c   De Braud, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Angiogenesis; Prognostic factors; Renal carcinoma; Targeted therapies; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX DIFFERENCE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DATABASES, FACTUAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84867401399     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.327     Document Type: Article

References (23)

1. Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B (2011) Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large openlabel study in diverse community settings. Ann Oncol 22(8): 1812-1823
2. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110(3): 543-550 (Pubitemid 47106142)
3. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 85(1): 60-66
4. Dixon Jr JR (1998) The international conference on harmonization good clinical practice guideline. Qual Assur 6(2): 65-74
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125-134 (Pubitemid 46089673)
6. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605): 2103-2111 (Pubitemid 350296300)
7. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton Jr JR, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23): 1655-1659 (Pubitemid 33126820)
8. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34): 5794-5799
9. Ljungberg B, Mehle C, Stenling R, Roos G (1996) Heterogeneity in renal cell carcinoma and its impact on prognosis - a flow cytometric study. Br J Cancer 74(1): 123-127 (Pubitemid 26231989)
10. Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Negrier S, Escudier B, Eisen T, Dutcher J, Atkins M, Heng DY, Choueiri T, Motzer R, Bukowski R, International Kidney Cancer Working Group (2011) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin Cancer Res 17: 5443-5450
11. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23(4): 832-841 (Pubitemid 46224183)
12. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286): 966-970 (Pubitemid 32913522)
13. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3): 454-463 (Pubitemid 41079774)
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 372(9637): 449-456
15. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530-2540 (Pubitemid 29368255)
16. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18(9): 1928-1935 (Pubitemid 30261931)
17. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22(2): 295-300
18. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E (2011b) Sorafenib with interleukin-2 vssorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 104(8): 1256-1261
19. Procopio G, Verzoni E, Iacovelli R, Guadalupi V, Gelsomino F, Buzzoni R (2011a) Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther 11(11): 1631-1640
20. Rini BI, Escudier B, Tomczak P, Kaprin A, Hutson TE, Szczylik C, Tarazi JC, Rosbrook B, Kim S, Motzer RJ (2011) Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 29, (abstr 4503)
21. Volpe A, Patard JJ (2010) Prognostic factors in renal cell carcinoma. World J Urol 28(3): 319-327
22. You D, Jeong IG, Ahn JH, Lee DH, Lee JL, Hong JH, Ahn H, Kim CS (2011) The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol 185(1): 54-59
23. Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T (2012) Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU Int 109(9): 1349-1354